Naudin T, Thorel D, Tétart F, Muraine M, Gueudry J
Service d'ophtalmologie, hôpital Charles-Nicolle, CHU Rouen, 76000 Rouen, France.
Service de dermatologie, hôpital Charles-Nicolle, CHU Rouen, 76000 Rouen, France.
J Fr Ophtalmol. 2021 Sep;44(7):1021-1028. doi: 10.1016/j.jfo.2020.09.037. Epub 2021 Jun 23.
Meibomian gland dysfunction (MGD) is the most common cause of dry eye syndrome. The goal of this study was to evaluate the efficacy of combined intense pulsed light (IPL) and low-level light therapy (LLLT) in symptomatic MGD.
This retrospective study analyzed data from 30 patients with MGD causing dry eye symptoms not relieved by medical therapy and managed with combined IPL and LLLT. The primary endpoint was the Ocular Score Disease Index (OSDI) score at 1 month and 1 year. Secondary endpoints were visual acuity, intraocular pressure, tear film break-up time, Schirmer's test, Oxford score, and infrared meibographic score at 1 month after the conclusion of treatment.
The mean OSDI score decreased from 43±19 to 17±12 (1 month; p<0.0001) and then to 29±11 (12 months; p=0.013); 63% of patients were meibographic grade 2 before versus 7% after treatment (range, 1-4) (p=0.009); 75% of patients were Oxford grade 1 before versus 41% after treatment (p=0.004) (range, 1-3). No significant difference in the other secondary endpoints was noted.
Over time, IPL therapy in combination with LLLT appears to improve patients with symptomatic MGD resistant to medical therapy.
睑板腺功能障碍(MGD)是干眼综合征最常见的病因。本研究的目的是评估强脉冲光(IPL)和低强度光疗(LLLT)联合治疗有症状MGD的疗效。
这项回顾性研究分析了30例因MGD导致干眼症状且药物治疗无效而接受IPL和LLLT联合治疗的患者的数据。主要终点是1个月和1年时的眼表疾病指数(OSDI)评分。次要终点是治疗结束后1个月时的视力、眼压、泪膜破裂时间、泪液分泌试验、牛津评分和红外睑板腺造影评分。
平均OSDI评分从43±19降至17±12(1个月;p<0.0001),然后降至29±11(12个月;p=0.013);63%的患者治疗前睑板腺造影为2级,治疗后为7%(范围1-4)(p=0.009);75%的患者治疗前牛津评分为1级,治疗后为41%(p=0.004)(范围1-3)。其他次要终点未发现显著差异。
随着时间的推移,IPL联合LLLT治疗似乎能改善对药物治疗耐药的有症状MGD患者。